Asset profile
HTI vaccine (ChAdOx1.HTI/MVA.HTI)
Vaccine
Evidence outlook · no controlled comparison
AELIX-003 (NCT04364035) · HIV/AIDS
The lead study's design has limits that temper confidence (see the rationale below), and it produced no formal comparison against a control. This tier describes the design, not an outcome.
AELIX-003 (NCT04364035): The study randomized 50 participants to vaccine-plus-vesatolimod or placebo and used quadruple blinding, with primary endpoints measuring Grade 3 or 4 reactions and serious adverse events. Because the registry has no posted results, whether the primary endpoints were met or missed is unknown, supporting a moderate evidence grade rather than a strong one.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 32 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HTI Vaccine (ChAdOx1.HTI / MVA.HTI): this drug | Phase 2 | Vaccine | HIV-1 conserved epitopes (HTI) | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Fosamprenavir (Lexiva / Telzir) | Approved | Small molecule | HIV protease | ||
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 | ||
| Ibalizumab (Trogarzo) | Approved | Monoclonal antibody | CD4 receptor | ||
| Lenacapavir (Sunlenca / Yeztugo) | Approved | Small molecule | HIV capsid | ||
| Maraviroc (Selzentry / Celsentri) | Approved | Small molecule | CCR5 co-receptor |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.